Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued to investors on Wednesday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 price objective on shares of Aptose Biosciences in a research report on Tuesday, December 10th.

Aptose Biosciences Stock Down 6.2 %

Shares of APTO stock opened at $0.21 on Wednesday. Aptose Biosciences has a 12-month low of $0.13 and a 12-month high of $2.60. The firm has a 50-day moving average price of $0.26 and a 200 day moving average price of $0.41. The company has a market capitalization of $12.83 million, a P/E ratio of -0.07 and a beta of 0.87.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp boosted its position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.